Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2007 May 20;25(15):2035-41.
doi: 10.1200/JCO.2006.08.9607.

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy

Andrew J Stephenson  1 , Peter T Scardino, Michael W Kattan, Thomas M Pisansky, Kevin M Slawin, Eric A Klein, Mitchell S Anscher, Jeff M Michalski, Howard M Sandler, Daniel W Lin, Jeffrey D Forman, Michael J Zelefsky, Larry L Kestin, Claus G Roehrborn, Charles N Catton, Theodore L DeWeese, Stanley L Liauw, Richard K Valicenti, Deborah A Kuban, Alan Pollack
Affiliations

Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy

Andrew J Stephenson et al. J Clin Oncol. .

Erratum in

  • J Clin Oncol. 2007 Sep 10;25(26):4153

Abstract

Purpose: An increasing serum prostate-specific antigen (PSA) level is the initial sign of recurrent prostate cancer among patients treated with radical prostatectomy. Salvage radiation therapy (SRT) may eradicate locally recurrent cancer, but studies to distinguish local from systemic recurrence lack adequate sensitivity and specificity. We developed a nomogram to predict the probability of cancer control at 6 years after SRT for PSA-defined recurrence.

Patients and methods: Using multivariable Cox regression analysis, we constructed a model to predict the probability of disease progression after SRT in a multi-institutional cohort of 1,540 patients.

Results: The 6-year progression-free probability was 32% (95% CI, 28% to 35%) overall. Forty-eight percent (95% CI, 40% to 56%) of patients treated with SRT alone at PSA levels of 0.50 ng/mL or lower were disease free at 6 years, including 41% (95% CI, 31% to 51%) who also had a PSA doubling time of 10 months or less or poorly differentiated (Gleason grade 8 to 10) cancer. Significant variables in the model were PSA level before SRT (P < .001), prostatectomy Gleason grade (P < .001), PSA doubling time (P < .001), surgical margins (P < .001), androgen-deprivation therapy before or during SRT (P < .001), and lymph node metastasis (P = .019). The resultant nomogram was internally validated and had a concordance index of 0.69.

Conclusion: Nearly half of patients with recurrent prostate cancer after radical prostatectomy have a long-term PSA response to SRT when treatment is administered at the earliest sign of recurrence. The nomogram we developed predicts the outcome of SRT and should prove valuable for medical decision making for patients with a rising PSA level.

PubMed Disclaimer

Conflict of interest statement

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.

AUTHORS’ DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Although all authors completed the disclosure declaration, the following authors or their immediate family members indicated a financial interest. No conflict exists for drugs or devices used in a study if they are not being evaluated as part of the investigation. For a detailed description of the disclosure categories, or for more information about ASCO’s conflict of interest policy, please refer to the Author Disclosure Declaration and the Disclosures of Potential Conflicts of Interest section in Information for Contributors.

Employment: N/A Leadership: Kevin M. Slawin, Oncovance Technologies Consultant: Peter T. Scardino, Oncovance Technologies; Michael W. Kattan, Oncovance Technologies Stock: N/A Honoraria: N/A Research Funds: N/A Testimony: N/A Other: N/A

Figures

Fig 1
Fig 1
(A) Kaplan-Meier estimate of the overall progression-free probability after salvage radiotherapy. (B) Progression-free probability after salvage radiotherapy stratified by preradiotherapy prostate-specific antigen 0.50 or less (blue), 0.51 to 1.00 (yellow), 1.01 to 1.50 (gray), and more than 1.50 ng/mL (red).
Fig 2
Fig 2
Four-year progression-free probability after salvage radiotherapy for 1,326 patients who did not receive androgen-deprivation therapy before or during radiation therapy, stratified by preradiotherapy prostate-specific antigen (PSA), Gleason score, surgical margins, and PSA doubling time (PSADT). RT, radiotherapy; PFP, progression-free probability; CI, 95% CI.
Fig 3
Fig 3
(A) Pretreatment nomogram predicting 6-year progression-free probability after salvage radiotherapy for prostate-specific antigen (PSA) recurrence after radical prostatectomy. (B) Calibration of the nomogram. Dashed line indicates reference line where an ideal nomogram would lie. Solid line indicates the performance of the current nomogram. Dots are quartiles of our data set. Instructions: Locate the patient’s Gleason score on the respective axis. Draw a straight line up to the Points axis to determine how many points toward disease recurrence that the patient receives for his or her Gleason score. Repeat this process for the other 10 disease and treatment parameters. Sum the points and locate this number on the Total Points axis. Draw a straight line down to find the patient’s probability of remaining free of disease progression at 6 years after salvage radiotherapy, provided the patient does not die of another cause first.
See this image and copyright information in PMC

References

    1. Bianco FJ, Jr, Scardino PT, Eastham JA. Radical prostatectomy: Long-term cancer control and recovery of sexual and urinary function (“trifecta”) Urology. 2005;66:83–94. - PubMed
    1. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA. 1999;281:1591–1597. - PubMed
    1. Anscher MS, Clough R, Dodge R. Radiotherapy for a rising prostate-specific antigen after radical prostatectomy: The first 10 years. Int J Radiat Oncol Biol Phys. 2000;48:369–375. - PubMed
    1. Catton C, Gospodarowicz M, Warde P, et al. Adjuvant and salvage radiation therapy after radical prostatectomy for adenocarcinoma of the prostate. Radiother Oncol. 2001;59:51–60. - PubMed
    1. Cheung R, Kamat AM, de Crevoisier R, et al. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys. 2005;63:134–140. - PubMed

Publication types

Substances